Natrilix Sr (Indapamide)

Indapamide blocks the sodium‑chloride transporter in the distal convoluted tubule of the kidney, decreasing reabsorption of these ions. This promotes loss of sodium, chloride, and water in the urine, lowering plasma volume and, through a direct vasodilatory effect, reducing peripheral vascular resistance, which together lower blood pressure.

The appropriate dose of Natrilix SR is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal function. Dosage may be adjusted during treatment, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for indapamide in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile before prescribing it to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Natrilix SR. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indapamide offers a combined diuretic and vasodilatory effect, which can provide effective blood pressure control with a lower incidence of certain metabolic disturbances compared with some thiazide diuretics. Its sustained‑release formulation allows once‑daily dosing, which may improve adherence relative to immediate‑release alternatives.

Store Natrilix SR tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Natrilix SR is taken orally, usually once daily in the morning with or without food, as directed by a healthcare professional. Swallow the tablet whole; do not crush, split, or chew the sustained‑release tablet to maintain its intended release profile.

Serious risks include severe electrolyte disturbances such as marked hypokalemia or hyponatremia, acute kidney injury indicated by a rapid rise in serum creatinine, and rare allergic reactions like rash or angioedema. Patients should seek medical attention promptly if they experience muscle weakness, irregular heartbeat, sudden swelling, or signs of an allergic response.

Natrilix SR should be avoided in individuals with known hypersensitivity to indapamide or other sulfonamide‑derived drugs, in patients with severe hepatic impairment, and in those with uncontrolled electrolyte imbalances. Clinicians will also assess suitability in patients with severe renal dysfunction or certain cardiac conditions.